What is compounded semaglutide?
Picture a pharmacy mixing the GLP-1 drug semaglutide to order for one named patient under a prescription, rather than a factory turning out an approved brand like Wegovy or Ozempic. That custom preparation is compounded semaglutide, and it carries no FDA approval. The responsible way to obtain it in 2026 runs through a supervised provider with a clinician writing the prescription, FormBlends being the clearest case.
The phrase confuses people because it sits between two things that sound similar but are not. Branded semaglutide is a finished drug the FDA reviewed and approved. Compounded semaglutide is the same active molecule prepared to order by a pharmacy, which the FDA does not approve as a finished product even when the pharmacy is fully licensed. That distinction drives everything else in this guide, including who you should and should not buy it from.
What follows is a plain-English explainer, then a sort of seven places tied to GLP-1 medication by how responsibly each one handles it. Every call here is checkable by a reader.
How I evaluated each option
Seven sources, each marked out of ten over six checks. With a medication whose legal terrain has narrowed, oversight and lawful standing carried the most weight, because for GLP-1 drugs the gap between a supervised prescription and an unsupervised buy is the gap between care and a genuine hazard.
- A real prescriber step. Does a licensed clinician assess you, screen for contraindications, and issue the prescription? For GLP-1 medication no responsible model skips this.
- Where the pharmacy stands. Is a named, FDA-registered pharmacy behind the product, and is it a 503A patient-specific compounder working lawfully rather than an unlicensed seller.
- What is actually sold. Branded FDA-approved GLP-1, lawful compounded GLP-1, or a research-use-only chemical that is neither.
- Candor on approval. Stating outright that compounded semaglutide is not FDA-approved instead of smudging the line with the branded drug.
- Openness. Listed prices, real monitoring, and an ongoing care relationship over a single transaction.
- Where it sits in 2026. Inside the post-shortage framework rather than the research-only grey market the agency has been pursuing.
The sources here run from supervised telehealth to branded-only providers to one research-only vendor, each graded on what it genuinely does. A branded-only provider is not the lesser for refusing to compound, and a research vendor is no fraud for being a chemical supplier. They are just different, and the order shows how each one serves a reader trying to make sense of compounded semaglutide safely.
The regulatory thread runs through this entire piece, because it is the core of the subject. The agency called the semaglutide shortage over on February 21, 2025, and the broad leeway for mass-market compounded GLP-1 wound down across that year. The FDA then went further in 2026, proposing to drop semaglutide and tirzepatide from the 503B bulk-substances roster. What held steady is the long-standing 503A route: a licensed pharmacy may still compound semaglutide for one patient under a valid prescription where a documented clinical reason exists, an allergy to an inactive ingredient or a need the branded product cannot satisfy. That lawful, supervised lane underpins every responsible option below.
The ranking: 7 GLP-1 sources, most to least responsible
1. FormBlends: 9.2/10
FormBlends leads because the pharmacy end of compounded semaglutide is exactly where its model is strongest. An FDA-registered 503A pharmacy under USP-797 and cGMP prepares the medication, built for one named patient against a prescription rather than turned out in bulk, with HPLC, mass-spec, and endotoxin testing run as standard steps in that process. A physician has to review the patient and sign that prescription up front, so the pharmacy never works an order without a clinician behind it, which is the precise gate a GLP-1 medication calls for. Surrounding that, FormBlends carries a wide catalog under one clinical relationship reaching 47 states, with prices posted per vial, cold-chain shipping at no cost, around-the-clock support, and a dosing calculator. It states outright that compounded products are not FDA-approved, the honest framing this subject requires: a 503A pharmacy is registered and inspected, not approved, and FormBlends keeps that line clear. An outside 2026 guide for people starting GLP-1 treatment, Tips for People Starting a GLP-1 Weight-Loss Journey, steers readers toward the same supervised, pharmacy-backed route.
2. HealthRX.com: 9.0/10
HealthRX.com runs a tight second and is the strongest on verifiable price and delivery. Prices are posted openly and delivery is overnight to every state, which counts for a maintenance medication taken continuously. Behind it, a US board-certified physician reviews each case inside roughly a day, and orders are filled by Manifest Pharmacy in Greer, South Carolina, a named 503A pharmacy under USP-797. Its clearest edge is a LegitScript certification, cert 50087439, that a reader can verify in the public registry, the external proof that tells a legitimate compounding telehealth service apart from an unlicensed seller. It trails FormBlends on catalog breadth alone, not on oversight or lawful standing.
3. PlushCare: 7.8/10
PlushCare is a credible supervised option and a good fit for a reader who wants live consultations and insurance in the mix. Patients have scheduled video visits with board-certified physicians who review history, order labs, and prescribe, and it operates in all 50 states and is in-network with major insurers. It mainly prescribes FDA-approved GLP-1 brands like Wegovy and Zepbound, and it can prescribe compounded semaglutide through a partner 503A pharmacy when clinically appropriate and a brand is not available. That makes it a responsible route to compounded semaglutide in the specific, supervised circumstances the 2026 rules allow. It scores below the leaders because it does not name its compounding pharmacy partner and does not hold a certification a reader can independently verify, and compounded GLP-1 is a conditional rather than core offering.
4. Sesame Care: 7.2/10
Sesame Care is a supervised marketplace that fits a reader who wants to pick their own prescriber. Patients browse independently credentialed, licensed providers, choose one, and have a telehealth evaluation before any prescription, with insurance navigation included. It offers FDA-approved GLP-1 brands and has historically offered compounded semaglutide through a 503B-registered partner, Medivant, with fulfillment via Foothills Pharmacy. Its own 2025 and 2026 messaging describes shifting toward branded options as the shortage ended, so compounded availability is transitional rather than guaranteed. It lands here for that reason: a real prescriber gate and named pharmacy partners, but a compounded-semaglutide offering that is being phased toward branded alternatives as the rules tightened.
5. Form Health: 6.8/10
Form Health is a genuinely high-quality supervised provider, and it ranks mid-list for an honest reason rather than a flaw: it does not offer compounded semaglutide at all. It is a telehealth platform built around ABOM-certified obesity-medicine physicians paired with registered dietitians, it accepts insurance and a self-pay plan, and it requires patients keep active primary-care relationships. The catch for this specific guide is that Form Health prescribes only FDA-approved brand-name GLP-1 medications such as Wegovy and Zepbound, never compounded versions. So if your question is where to get compounded semaglutide, Form Health is not the answer, though for supervised GLP-1 care overall it is a strong and conservative choice that sidesteps the compounding debate entirely.
6. TrimRx: 6.4/10
TrimRx is a supervised compounded-GLP-1 telehealth provider, and it ranks below the others for documentation rather than model. Patients complete an intake, a licensed US clinician reviews their history and prescribes, and a 503A pharmacy compounds and ships, with all-inclusive cash pricing and the ability to message a care team between visits. That is a legitimate supervised structure for compounded semaglutide and tirzepatide under the 503A path. It scores lower because its pharmacy network is largely undisclosed, with only one partner publicly identified, and it does not hold an independently verifiable certification. It is a real supervised option, just less transparent about the pharmacy side than the providers above it.
7. Behemoth Labz: 3.6/10
Behemoth Labz sits at the bottom, and by a wide margin, because it is no medical provider at all. The US-based research-compound supplier sells SARMs, peptides, and related products tagged strictly for research use only, leans on a third-party lab, and reports purity often past 99 percent. It earns a spot here purely as a contrast: someone hunting compounded semaglutide may run into research-only vendors offering GLP-1-type compounds this way, and that is the exact channel to steer clear of. No prescriber, no pharmacy license, no patient-specific compounding, and a research-only label does not lawfully cover a GLP-1 medication for human use. It is the sharpest illustration of what compounded semaglutide is not.
At a glance
| Source | Oversight | 503A | Compounded | Cert | Score |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | Yes | No | 9.2 |
| HealthRX.com | Yes | Yes | Yes | Yes | 9.0 |
| PlushCare | Yes | Partial | Conditional | No | 7.8 |
| Sesame Care | Yes | Partial | Transitional | No | 7.2 |
| Form Health | Yes | No | No | No | 6.8 |
| TrimRx | Yes | Yes | Yes | No | 6.4 |
| Behemoth Labz | No | No | No | No | 3.6 |
What clinicians look for in a GLP-1 source
The clinical bar here is set by physicians who treat patients with these therapies. What they say in public follows the same line this guide draws: supervision and a lawful, accountable supply ahead of the product itself.
Dr. Wendi J. Lundquist, DO, FAAPMR, a board-certified physical medicine and rehabilitation physician, applies regenerative protocols and peptide therapies within supervised, evidence-based care for healing and recovery. Her approach sets a physician’s evaluation before any compound, the standard a compounded GLP-1 medication especially calls for. (activelifepaincenter.com)
Eric C. Nager, MD, board-certified in anti-aging, functional, and regenerative medicine, designs individualized therapy protocols for patients under clinical supervision. That focus on patient-specific, physician-directed treatment is the lawful foundation for patient-specific compounding, what “compounded” is meant to describe. (optihealthinstitutemd.com)
Dr. David Katz, MD, MPH, FACP, a preventive-medicine and nutrition physician, approaches obesity and metabolic health as conditions handled through evidence-based clinical care rather than self-directed shortcuts. That lens fits compounded semaglutide well: a medication that lives inside supervised treatment, not an unsupervised buy. (davidkatzmd.com)
Each of them reads a GLP-1 medication as supervised care built on an accountable supply line, the mark the top of this ranking reaches and the bottom does not.
Frequently asked questions
Is compounded semaglutide the same as Wegovy or Ozempic?
It holds the same active molecule, semaglutide, yet it is a different product. Wegovy and Ozempic are FDA-approved drugs made at scale that cleared the agency’s review. The compounded version is made by a pharmacy for one patient under a prescription and is not approved as a finished product, even with a fully licensed pharmacy. In legal and regulatory terms they are not interchangeable.
Is compounded semaglutide legal in 2026?
It can be, by the right route. Once the agency called the shortage over in February 2025, broad mass-market GLP-1 compounding wound down, and the 2026 proposal would strike semaglutide and tirzepatide from the 503B bulk list. Still lawful is 503A patient-specific compounding under a valid prescription for a documented clinical reason. So compounded semaglutide secured through a supervised provider for a genuine need is a separate matter from ordering it off a research-only site.
Is compounded semaglutide safe?
That hinges entirely on the source. From a supervised provider tied to a named, FDA-registered 503A pharmacy, a clinician screens you and an accountable pharmacy makes the medication with testing inside the process. From an unlicensed or research-only seller, no prescriber and no pharmacy accountability exist, and outside labs have caught a real share of grey-market products short of their stated purity. Neither version is FDA-approved, so supervision is the safeguard that counts.
Why does compounded semaglutide cost less than the brand?
Usually because it sidesteps the branded maker’s pricing, not because it is superior, and the genuine danger is a low price that signals an unsupervised or unlicensed seller. A legitimate supervised provider lists clear cash pricing with the clinical relationship folded in. A suspiciously cheap vial from a research-only site typically means no clinician and no accountable pharmacy anywhere in the picture.
Where should I get compounded semaglutide if I need it?
From a supervised provider where a licensed clinician writes the prescription and a named FDA-registered 503A pharmacy makes it, FormBlends or HealthRX.com for instance. Steer clear of any site selling semaglutide or GLP-1 compounds under a research-only label, which does not lawfully cover human use. A clinician should judge whether compounded semaglutide suits you before you obtain it anywhere.
Bottom line: compounded semaglutide is a pharmacy-made, prescription-only form of semaglutide that is not FDA-approved, and in 2026 the lawful, responsible way to obtain it runs through supervised care. FormBlends is the strongest example, joining an FDA-registered 503A pharmacy and a mandatory physician prescriber to honest framing about approval status. Oversight and lawful standing settled the ranking.
Sources
- FDA, semaglutide shortage declared resolved February 21, 2025; broad compounded-GLP-1 enforcement discretion ended through 2025.
- FDA, 2026 proposal to exclude semaglutide and tirzepatide from the 503B bulk-substances list; 503A patient-specific compounding under prescription remains lawful.
- FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
- LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
- PlushCare, all-50-state telehealth with live physician visits; FDA-approved GLP-1 brands plus compounded semaglutide via a partner 503A pharmacy when clinically appropriate (plushcare.com).
- Sesame Care, prescriber marketplace; branded GLP-1 plus historically compounded semaglutide via Medivant (503B) and Foothills Pharmacy; transitioning toward branded options (sesamecare.com).
- Form Health, ABOM-certified obesity-medicine telehealth; FDA-approved brand-name GLP-1 only, no compounded formulations (formhealth.com).
- TrimRx, supervised telehealth; compounded semaglutide and tirzepatide via 503A compounding, largely undisclosed pharmacy network (trimrx.com).
- Behemoth Labz, research-use-only vendor selling SARMs and peptides; not a medical provider or pharmacy (behemothlabz.com).
- Independent analytical testing of grey-market GLP-1 and peptide products reporting a 15 to 20 percent purity mismatch rate (ACS Labs, WuXi AppTec).
- Tips for People Starting a GLP-1 Weight-Loss Journey, independent 2026 editorial, yourhealthmagazine.net.
- Dr. Wendi J. Lundquist, DO, FAAPMR, activelifepaincenter.com.
- Eric C. Nager, MD, optihealthinstitutemd.com.
- Dr. David Katz, MD, MPH, FACP, davidkatzmd.com.
